Moderna, Inc. (MRNA) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 10:00 AM EDT
Company Participants
Stephen Hoge – President
Conference Call Participants
Terence Flynn – Morgan Stanley, Research Division
Presentation
Terence Flynn
Morgan Stanley, Research Division
Thanks for joining us, everybody. I’m Terence Flynn, Morgan Stanley’s U.S. biopharma analyst. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative. Very pleased to be hosting Moderna this morning.
From the company, we have Stephen Hoge, the company’s President. Stephen, thanks so much for being here. Really enjoy an opportunity to get to speak with you today. I guess, first, what I wanted to start off with is the INT program is front and center. Congratulations on the positive Phase III adjuvant melanoma data.
Question-and-Answer Session
Terence Flynn
Morgan Stanley, Research Division
So maybe just talk to us about the implications of that data for the broader strategy at Moderna in terms of what does this mean for additional indications? What does this mean for leaning in on the program? Just high level before we dig into some of the data questions that I have.
Stephen Hoge
President
Of course. Well, first, thank you again for having us. Always a pleasure to be here. So look, we’re obviously thrilled by the results that were announced. It’s the idea of a T-cell priming approach, a vaccine, if you will, approach to treating cancer has been long promised, but this is the first time that we’ve been able to see a statistically significant and clinically meaningful result, as we said in our press release. It was also the first time we’ve ever — anybody has ever achieved that kind of benefit over KEYTRUDA in the adjuvant setting in melanoma. And that’s not because there wasn’t a lot of attempts.